GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (NYSE:LLY) » Definitions » Price-to-Free-Cash-Flow

Eli Lilly and Co (Eli Lilly and Co) Price-to-Free-Cash-Flow

: N/A (As of Today)
View and export this data going back to 1970. Start your Free Trial

As of today (2024-04-16), Eli Lilly and Co's share price is $750.77. Eli Lilly and Co's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.50. Hence, Eli Lilly and Co's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Eli Lilly and Co's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 13 years, Eli Lilly and Co's highest Price-to-Free-Cash-Flow Ratio was 165.06. The lowest was 11.46. And the median was 37.19.

LLY's Price-to-Free-Cash-Flow is not ranked *
in the Drug Manufacturers industry.
Industry Median: 20.74
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Eli Lilly and Co's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-2.17. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-3.50.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Eli Lilly and Co was -168.60% per year.

During the past 13 years, Eli Lilly and Co's highest 3-Year average Free Cash Flow per Share Growth Rate was 116.20% per year. The lowest was -30.90% per year. And the median was 10.90% per year.


Eli Lilly and Co Price-to-Free-Cash-Flow Historical Data

The historical data trend for Eli Lilly and Co's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.30 34.46 46.75 71.94 -

Eli Lilly and Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 71.94 82.00 132.00 - -

Competitive Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co Price-to-Free-Cash-Flow Distribution

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Price-to-Free-Cash-Flow falls into.



Eli Lilly and Co Price-to-Free-Cash-Flow Calculation

Eli Lilly and Co's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=750.77/-3.495
=N/A

Eli Lilly and Co's Share Price of today is $750.77.
Eli Lilly and Co's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.50.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Eli Lilly and Co  (NYSE:LLY) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Eli Lilly and Co Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co (Eli Lilly and Co) Business Description

Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Executives
Lilly Endowment Inc 10 percent owner 2801 NORTH MERIDIAN ST, INDIANAPOLIS IN 46208
Donald A Zakrowski officer: Chief Accounting Officer LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Alonzo Weems officer: SVP, ERM & CECO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Patrik Jonsson officer: SVP and Pres., Lilly Bio-Meds LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Anne E. White officer: SVP & Pres-Lilly Oncology LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Eric Dozier officer: EVP, HR & Diversity LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Jackson P Tai director
Mary Lynne Hedley director C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Marschall S Runge director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Naarden Jacob Van officer: SVP, CEO LoxoONC, Pres LlyONC C/O ELI LILLY & CO, LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Diogo Rau officer: SVP & CIDO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Edgardo Hernandez officer: SVP & Pres., Mfg. Operations LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Kimberly H Johnson director C/O FANNIE MAE, 1100 15TH STREET, NW, WASHINGTON DC 20005
Anat Ashkenazi officer: SVP & CFO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Gabrielle Sulzberger director 450 LEXINGTON AVENUE, FLOOR 13, NEW YORK NY 10017